Document is current
Any future updates will be listed below
-
Authors
Millul, Jacopo
Basaco Bernabeu, Tais
Gaonkar, Raghuvir H.
De Rose, Francesco
Jaafar-Thiel, Leila
Ulaner, Gary A.
Mansi, Rosalba
Fani, Melpomeni https://orcid.org/0000-0002-9309-1604
-
Funding
Funding for this research was provided by:
Innosuisse - Schweizerische Agentur für Innovationsförderung (100.918 IP-LS)
University of Basel
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 9 August 2025
First Online: 21 August 2025
Declarations
:
: Not applicable.
: Not applicable.
: Melpomeni Fani reports research funding from Ipsen, ITM and Nuclidium and acts as a scientific advisor of Nuclidium AG. Jacopo Millul and Melpomeni Fani are co-inventors on patent applications filed by Nuclidium AG and the University of Basel related to 61Cu-labeled ligands. Francesco De Rose and Leila Jaafar-Thiel are employees of Nuclidium AG and co-inventors in a series of patent related to 61Cu-labeled tracers. Gary A. Ulaner discloses he receives speaker fees and research support from Lantheus, GE Healthcare, and RayzeBio, as well as serves on the Scientific Advisory Boards of Lantheus, GE Healthcare, RayzeBio, and Nuclidium.
